Epidiolex cannabidiol: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 171 patients ages 2-55 with LGS uncontrolled on >=1 anti-epileptic drug

Read the full 211 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE